Stock Events

Stock Events

Precigen 

$7.20
77
-$0.24-3.23% Friday 20:00
-$0.02-0.28%Friday 23:30After hours

Statistics

Day High
7.2
Day Low
7.18
52W High
7.5
52W Low
2.99
Volume
131,600
Avg. Volume
-
Mkt Cap
2.58B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.06
-0.69
-0.32
0.05
Expected EPS
0.05
Actual EPS
N/A

Financials

-4,436.62%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
9.68MRevenue
-429.64MNet Income

Analyst Ratings

14.50Average Price Target
The highest estimate is 18.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PGEN. It's not an investment recommendation.
NVIDIA
16
NVDA
Tesla
12
TSLA
Realty Income
11
O
Alphabet
11
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is a competitor because it focuses on gene editing technologies, similar to Precigen's gene and cell therapy work.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine operates in the gene editing space, directly competing with Precigen's efforts in developing gene therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is involved in CRISPR/Cas9 gene editing, a similar field to Precigen's gene therapy and editing technologies.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals focuses on RNAi (RNA interference) therapeutics, which is a different but competing approach to Precigen's gene and cell therapy techniques.
Beam Therapeutics
BEAM
Mkt Cap2.76B
Beam Therapeutics competes with Precigen through its development of precision genetic medicines using base editing, a novel form of gene editing.
Fate Therapeutics
FATE
Mkt Cap307.94M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, competing with Precigen's work in cell therapy.

About

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Show more...
CEO
Helen Sabzevari
Employees
47
Country
United States
ISIN
US74017N1054
WKN
000A2PZG1

Listings

STU
DE
I5X.STU
XNAS
US
PGEN
MU
DE
I5X.MU
BOATS
BOATS
PGEN.BOATS

0 Comments

Share your thoughts

FAQ

What is Precigen stock price today?▼
The current price of PGEN is $7.20 USD — it has decreased by -3.23% in the past 24 hours. Watch Precigen stock price performance more closely on the chart.
What is Precigen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Precigen stocks are traded under the ticker PGEN.
Is Precigen stock price growing?▼
PGEN stock has risen by +18.03% compared to the previous week, the month change is a +29.96% rise, over the last year Precigen has showed a +72.25% increase.
What is Precigen market cap?▼
Today Precigen has the market capitalization of 2.58B
When is the next Precigen earnings date?▼
Precigen is going to release the next earnings report on November 05, 2026.
What were Precigen earnings last quarter?▼
PGEN earnings for the last quarter are 0.05 USD per share, whereas the estimation was -0.01 USD resulting in a +514.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Precigen revenue for the last year?▼
Precigen revenue for the last year amounts to 9.68M USD.
What is Precigen net income for the last year?▼
PGEN net income for the last year is -429.64M USD.
How many employees does Precigen have?▼
As of August 23, 2026, the company has 47 employees.
In which sector is Precigen located?▼
Precigen operates in the Health & Wellness sector.
When did Precigen complete a stock split?▼
Precigen has not had any recent stock splits.
Where is Precigen headquartered?▼
Precigen is headquartered in GERMANTOWN, United States.